research use only
Cat.No.S4530
|
In vitro |
Water : 36 mg/mL
DMSO
: 6 mg/mL
(33.3 mM)
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 180.16 | Formula | C6H12O6 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 87-89-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | myo-inositol | Smiles | C1(C(C(C(C(C1O)O)O)O)O)O | ||
| In vitro |
In vitro, i-Inositol is able to improve the sperm mitochondrial function in patients with altered sperm parameters.
|
|---|---|
| In vivo |
Myo-Inositol (MI) is one of the most abundant metabolites in the human brain located mainly in glial cells and functions as an osmolyte. its concentration is altered in many brain disorders. This compound is a key precursor of membrane phospho-inositides and phospholipids and it is also involved in cell membrane and myelin sheet structures. The addition of this chemical to folic acid in non PCOS-patients undergoing multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of rFSH whilst maintaining clinical pregnancy rate.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02811133 | Withdrawn | Bipolar Disorder|Anxiety Disorders|Anxiety |
Ronald M. Glick MD|The Fine Foundation|Jarrow Formulas Inc|University of Pittsburgh |
August 2023 | Phase 1|Phase 2 |
| NCT05777863 | Active not recruiting | Life Style|Risk Reduction|Cognitive Decline|Aging |
Donders Centre for Cognitive Neuroimaging|Wageningen University and Research |
May 10 2022 | Not Applicable |
| NCT05497414 | Recruiting | Major Depression |
Boston University Charles River Campus|One Mind|Brain & Behavior Research Foundation|1907 Foundation |
January 31 2022 | Not Applicable |
| NCT05098587 | Completed | Spinal Cord Injuries|Neuropathic Pain |
Swiss Paraplegic Research Nottwil|Haute Ecole de Santé Vaud |
August 30 2021 | -- |
| NCT05410314 | Completed | Lymphoma Hodgkin|Menstrual Irregularity|Fertility Disorders |
University of Bari Aldo Moro |
February 7 2020 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.